{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:23:48Z","timestamp":1782771828198,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81503147"],"award-info":[{"award-number":["81503147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872929"],"award-info":[{"award-number":["81872929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation of Zhejiang Traditional Chinese Medicine","award":["2016ZZ014"],"award-info":[{"award-number":["2016ZZ014"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bcp.2020.114021","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T21:38:22Z","timestamp":1588887502000},"page":"114021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy"],"prefix":"10.1016","volume":"177","author":[{"given":"Cui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2020.114021_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2020.114021_b0010","doi-asserted-by":"crossref","unstructured":"P. Prsa, B. Karademir, G. Bicim, H. Mahmoud, I. Dahan, A.S. Yalcin, J. Mahajna, I. Milisav, The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics, Biochem. Pharmacol. (2019).","DOI":"10.1016\/j.bcp.2019.06.007"},{"issue":"10","key":"10.1016\/j.bcp.2020.114021_b0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/10408444.2011.602662","article-title":"An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity","volume":"41","author":"Sanchez-Gonzalez","year":"2011","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.bcp.2020.114021_b0020","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3389\/fphar.2018.01111","article-title":"Genetic variations and cisplatin nephrotoxicity: a systematic review","volume":"9","author":"Zazuli","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2020.114021_b0025","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2020.114021_b0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ki.2013.330","article-title":"Pharmacological activation of NQO1 increases NAD (+) levels and attenuates cisplatin-mediated acute kidney injury in mice","volume":"85","author":"Oh","year":"2014","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.bcp.2020.114021_b0035","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/bjc.1998.276","article-title":"Cisplatin dose rate as a risk factor for nephrotoxicity in children","volume":"77","author":"Skinner","year":"1998","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2020.114021_b0040","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/bcp.13388","article-title":"Renal toxicity and chemotherapy in children with cancer","volume":"83","author":"Ruggiero","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114021_b0045","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00775-018-1579-z","article-title":"Platinum (II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin","volume":"23","author":"Alexander","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114021_b0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1293\/tox.24.87","article-title":"Comparative nephrotoxicity of cisplatin and nedaplatin: mechanisms and histopathological characteristics","volume":"24","author":"Uehara","year":"2011","journal-title":"J. Toxicol. Pathol."},{"issue":"19","key":"10.1016\/j.bcp.2020.114021_b0055","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"issue":"5","key":"10.1016\/j.bcp.2020.114021_b0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.bcp.2020.114021_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101902","article-title":"Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection","volume":"9","author":"Kidera","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2020.114021_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2020.114021_b0075","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/ndt\/12.12.2478","article-title":"Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application","volume":"12","author":"Kuhlmann","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.bcp.2020.114021_b0080","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","article-title":"Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care","volume":"61","author":"Launay-Vacher","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114021_b0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2020.114021_b0090","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00204-015-1633-3","article-title":"DNA damage response in cisplatin-induced nephrotoxicity","volume":"89","author":"Zhu","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114021_b0095","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"15","key":"10.1016\/j.bcp.2020.114021_b0100","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-14-0319","article-title":"Cisplatin-induced renal injury is independently mediated by OCT2 and p53","volume":"20","author":"Sprowl","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114021_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J. Nephrol."},{"issue":"50","key":"10.1016\/j.bcp.2020.114021_b0110","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2020.114021_b0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.phrs.2016.06.002","article-title":"Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics","volume":"111","author":"Wagner","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bcp.2020.114021_b0120","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bcp.2010.08.019","article-title":"Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity","volume":"80","author":"Nakamura","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114021_b0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neuropharm.2007.08.004","article-title":"Levo-tetrahydropalmatine inhibits cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats","volume":"53","author":"Xi","year":"2007","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2020.114021_b0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10571-007-9179-4","article-title":"Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction","volume":"28","author":"Chu","year":"2008","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2020.114021_b0135","article-title":"L-Tetrahydropalmatine, an active component of Corydalis yanhusuo W.T. Wang, protects against myocardial ischaemia-reperfusion injury in rats, PLoS","author":"Han","year":"2012","journal-title":"One 7(6)"},{"issue":"16","key":"10.1016\/j.bcp.2020.114021_b0140","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1111\/bph.13537","article-title":"Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride","volume":"173","author":"Li","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2020.114021_b0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00498254.2015.1056283","article-title":"Interaction of six protoberberine alkaloids with human organic cation transporters 1, 2 and 3","volume":"46","author":"Li","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2020.114021_b0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2014.03.005","article-title":"Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action","volume":"53","author":"Wang","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"issue":"7","key":"10.1016\/j.bcp.2020.114021_b0155","first-page":"842","article-title":"Establishment of MDCK cell models expressing human MATE1 or co-expressing with human OCT1 or OCT2","volume":"50","author":"Lei","year":"2015","journal-title":"Acta Pharm. Sin."},{"issue":"10","key":"10.1016\/j.bcp.2020.114021_b0160","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/AAC.00986-16","article-title":"Multiple drug transporters are involved in renal secretion of entecavir","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.bcp.2020.114021_b0165","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jps.23567","article-title":"Precise comparison of protein localization among OCT, OAT, and MATE in human kidney","volume":"102","author":"Motohashi","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2020.114021_b0170","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2217\/bmm-2016-0235","article-title":"Evaluation of novel biomarkers in nephrotoxicity","volume":"10","author":"Nayeri","year":"2016","journal-title":"Biomark. Med."},{"key":"10.1016\/j.bcp.2020.114021_b0175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-050214-013407","article-title":"Acute kidney injury","volume":"67","author":"Zuk","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.bcp.2020.114021_b0180","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1159\/000452592","article-title":"Evaluation of KIM-1 and NGAL as early indicators for assessment of gentamycin-induced nephrotoxicity in vivo and in vitro","volume":"41","author":"Luo","year":"2016","journal-title":"Kidney Blood Press. Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.114021_b0185","first-page":"1237","article-title":"Identification of cisplatin sensitizers through high-throughput combinatorial screening","volume":"53","author":"Sun","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114021_b0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/dmd.108.023911","article-title":"The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine","volume":"37","author":"Matsushima","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2020.114021_b0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2013.08.024","article-title":"Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)","volume":"273","author":"Li","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114021_b0200","doi-asserted-by":"crossref","unstructured":"Y.Q. Liu, X.L. Zheng, Q.Q. Yu, H. Wang, F.Q. Tan, Q.Y. Zhu, L.M. Yuan, H.D. Jiang, L.S. Yu, S. Zeng, Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin, Sci. Transl. Med. 8(348) (2016) 348ra97.","DOI":"10.1126\/scitranslmed.aaf3124"},{"issue":"4","key":"10.1016\/j.bcp.2020.114021_b0205","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/15384101.2017.1395533","article-title":"SOX9\/miR-130a\/CTR1 axis modulates DDP-resistance of cervical cancer cell","volume":"17","author":"Feng","year":"2018","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.bcp.2020.114021_b0210","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3109\/00498254.2012.702247","article-title":"The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP","volume":"42","author":"Sun","year":"2012","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.bcp.2020.114021_b0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/chir.22110","article-title":"Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes","volume":"25","author":"Sun","year":"2013","journal-title":"Chirality"},{"issue":"5","key":"10.1016\/j.bcp.2020.114021_b0220","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/chir.22020","article-title":"Stereoselective metabolism of tetrahydropalmatine enantiomers in rat liver microsomes","volume":"24","author":"Zhao","year":"2012","journal-title":"Chirality"},{"issue":"2A","key":"10.1016\/j.bcp.2020.114021_b0225","first-page":"863","article-title":"Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells","volume":"22","author":"Liu","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2020.114021_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/465897","article-title":"Induction of oxidative stress in kidney","volume":"2012","author":"Ozbek","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.bcp.2020.114021_b0235","doi-asserted-by":"crossref","unstructured":"G. Ciarimboli, D. Deuster, A. Knief, M. Sperling, M. Holtkamp, B. Edemir, H. Pavenstadt, C. Lanvers-Kaminsky, A. a. Zehnhoff-Dinnesen, A. H. Schinkel, H. Koepsell, H. Jurgens, E. Schlatter, Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions, Am. J. Pathol. 176(3) (2010) 1169-1180.","DOI":"10.2353\/ajpath.2010.090610"},{"issue":"27","key":"10.1016\/j.bcp.2020.114021_b0240","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc. NatI. Acad. Sci. U. S. A."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:20:19Z","timestamp":1757769619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220302483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":48,"alternative-id":["S0006295220302483"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114021","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114021"}}